In a discovery that may have significant impact on the future of colon cancer treatment and research, scientists at the Helen F. Graham Cancer & Research Institute’s Center for Translational Cancer Research at Christiana Care Health System have defined a key signaling pathway that regulates colon cancer growth.
Christiana Care has reduced opioids prescriptions by 40 percent after some ob-gyn and general surgery procedures, by almost 50 percent for patients discharged from the emergency department and by 37 percent for primary care patients.
To increase access to advanced neurological care, Christiana Care Health System has opened the first Epilepsy Monitoring Unit (EMU) in the First State.
Who owns CRISPR gene editing technology? Will insurance pay for gene editing procedures, and is it ethical to change human DNA? Experts addressed these questions on June 8 during CRISPR Gene Editing 360: From Laboratory Science to Ethical Application, a symposium held at Christiana Care's Christiana Hospital.
For ground-breaking scientific research in gene editing and an innovative partnership with Jerusalem-based NovellusDx to advance personalized cancer treatment, the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care received the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce on May 22.
Thanks to a $1 million National Science Foundation grant, Christiana Care’s Gene Editing Institute and Delaware Technical Community College developed a unique curriculum to include gene editing into two courses in its biological sciences program at its Stanton, Delaware campus.
Scientists at Christiana Care Health System’s Gene Editing Institute have developed a potentially breakthrough CRISPR gene-editing tool. It could allow researchers to take fragments of DNA extracted from human cells, put them into a test tube, and quickly and precisely engineer multiple changes to the genetic code, according to a new study published today in the CRISPR Journal.
For the seventh year in row, Christiana Care Health System’s Christiana and Wilmington hospitals have both been designated a Leader in LGBTQ Healthcare Equality from the Human Rights Campaign Foundation.
Unique partnership between health system and county in Delaware will help individuals receive addiction treatment and support after they are released from the emergency department following treatment from an opioid overdose.
In breakthrough colon cancer research, scientists at Christiana Care Health System’s Center for Translational Cancer Research (CTCR) of the Helen F. Graham Cancer Center & Research Institute have discovered that over-expression of HOXA4 and HOXA9 genes in colon cancer stem cells promotes cell replication and contributes to the overpopulation of stem cells that drives colon cancer development. The findings suggest treatment with vitamin A derivatives, called retinoid drugs, could provide a therapeutic strategy for decreasing the expression of these HOX genes and for targeting highly resistant cancer stem cells.
Christiana Care Health System is joining the Strata Precision Oncology Network to offer next-generation tumor profiling at no cost to patients with advanced or rare cancers. Based on the results, eligible patients will be matched to the best available clinical trials or most innovative therapy. The project begins on Feb. 1, 2018.
In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a revolutionary new blood test to diagnose breast cancer.
The world’s most revolutionary gene editing technology is coming to college classrooms in Delaware, thanks to a $1 million National Science Foundation grant awarded to the Delaware Technical Community College and the Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute.
The Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute signs agreement with ABS to modify cell lines to accelerate cancer therapies
Personalized cancer therapies are on the horizon thanks to a new genomic cancer research partnership between the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute and the biotechnology company NovellusDx.
Christiana Care Health System’s Christiana and Wilmington hospitals have both been designated a 2017 “Leader in LGBTQ Healthcare Equality,” receiving a perfect score on the national Healthcare Equality Index (HEI) from the Human Rights Campaign (HRC) Foundation.
Gene Editing Institute at Christiana Care Health System partners with NovellusDx in BIRD Foundation Grant
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right